US 11510939
RNAs for complement inhibition
granted A61KA61K31/713A61P
Quick answer
US patent 11510939 (RNAs for complement inhibition) held by Apellis Pharmaceuticals, Inc. expires Mon Nov 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Apellis Pharmaceuticals, Inc.
- Grant date
- Tue Nov 29 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Nov 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 16
- CPC classes
- A61K, A61K31/713, A61P, A61P43/00